Fluocinone topical solution can treat high fevers

Fluocyn is an oral anti-fungal drug that was approved by the Food and Drug Administration last year.

It was developed by Bristol-Myers Squibb, which is also a drugmaker.

But this week, Bristol- Myers Squirb and a small company in Switzerland announced that they had developed a topical formulation that can treat fevers with a lower risk of side effects than the drug.

The company, called Fluocini, developed the formulation using a different, non-invasive method, called a single-agent approach, or SAA.

In that approach, the patient is given a small amount of a solution containing fluocinolone (Fluocin) and a single, active ingredient, ketoconazol (Ketoconaz).

The patient takes the drug, which kills or clears the fungus, and the fungus dies.

This approach was first used in the treatment of flu-like symptoms in people with asthma and COPD.

The Pfizer-owned Bristol-MYERS Squibbs subsidiary said that it is working with the Swiss firm to commercialize the product and that it expects the product to be on the market within the next 12 to 18 months.

The FDA approved Fluocincinololol for treating fevers in October 2016, and a trial has shown that it works.

In a study published in September, researchers at the University of Michigan found that the formulation reduces the risk of death or severe respiratory distress after a flu-related episode by nearly 80 percent, compared to a placebo, and that the treatment significantly reduced the incidence of fever and fever-like illness.

In another trial published last month in the New England Journal of Medicine, the company reported that the FSCI study showed the FSK inhibitor reduced the severity of fever.

Keto-Cyn is the name for a non-steroidal anti-inflammatory drug (NSAID) marketed as an over-the-counter medicine, or OTC medicine.

It has been around since the 1970s, but has been widely used in recent years for the treatment or prevention of common conditions including allergies and psoriasis.

But its effectiveness has not been consistently proven.

Keto-Cinol was approved in 2008 and has been shown to be effective in treating mild to moderate cases of asthma, asthma exacerbations, bronchitis and allergies, but the drug has been associated with serious side effects.

In October, the FDA approved a version of the drug that targets the same receptors in the respiratory tract as keto-cinol, and in September it approved a new formulation that targets a different receptor in the lung, known as PAS-19.FSCI researchers are still testing the new formulation, and they are optimistic that it will be more effective than the FDA-approved formulation.

The Pfizer subsidiary said in a statement that it was working with Bristol-Meyers Squiber to commercialise the formulation and that they expect the product “to be on sale within the following 12 to 24 months.”